Published in Am J Respir Crit Care Med on August 01, 2015
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol (2016) 0.99
Genetic Modifiers of Progression-free Survival in Never-smoking Lung Adenocarcinoma Patients Treated with First-line TKIs. Am J Respir Crit Care Med (2016) 0.75
Molecular Role of EGFR-MAPK Pathway in Patchouli Alcohol-Induced Apoptosis and Cell Cycle Arrest on A549 Cells In Vitro and In Vivo. Biomed Res Int (2016) 0.75
Smoking and Lung Cancer: A Geo-Regional Perspective. Front Oncol (2017) 0.75
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med (2014) 9.94
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. Ann Intern Med (2013) 7.19
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med (2015) 7.11
Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med (2014) 6.95
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Lancet Oncol (2013) 6.12
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol (2015) 6.02
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol (2015) 5.95
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol (2015) 5.83
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest (2013) 4.83
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol (2015) 4.68
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med (2007) 4.63
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov (2014) 4.55
Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med (2013) 4.09
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol (2014) 4.02
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Asbestos, asbestosis, smoking, and lung cancer. New findings from the North American insulator cohort. Am J Respir Crit Care Med (2013) 3.61
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. Am J Respir Crit Care Med (2013) 3.47
Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg (1995) 3.31
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol (2011) 2.69
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol (2014) 2.66
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med (2013) 2.65
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol (2013) 2.59
Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol (2014) 2.57
Retracted HMGA2 functions as a competing endogenous RNA to promote lung cancer progression. Nature (2013) 2.47
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. Cancer Discov (2013) 2.46
New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol (2013) 2.25
EBUS-centred versus EUS-centred mediastinal staging in lung cancer: a randomised controlled trial. Thorax (2013) 2.21
A case-control study of long-term exposure to ambient volatile organic compounds and lung cancer in Toronto, Ontario, Canada. Am J Epidemiol (2013) 2.05
Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov (2013) 1.93
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov (2014) 1.88
Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg (2014) 1.86
Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol (2014) 1.85
MicroRNA-135b promotes lung cancer metastasis by regulating multiple targets in the Hippo pathway and LZTS1. Nat Commun (2013) 1.76
A blood-based proteomic classifier for the molecular characterization of pulmonary nodules. Sci Transl Med (2013) 1.69
The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell (2014) 1.65
Aiolos promotes anchorage independence by silencing p66Shc transcription in cancer cells. Cancer Cell (2014) 1.60
Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion. Am J Respir Crit Care Med (2014) 1.57
Endobronchial ultrasonography-guided transbronchial needle aspiration biopsy for preoperative nodal staging of lung cancer in a veteran population. JAMA Surg (2013) 1.48
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell (2014) 1.45
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med (2014) 1.39
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. J Clin Invest (2014) 1.33
Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A (2013) 1.32
High procedure volume is strongly associated with improved survival after lung cancer surgery. J Clin Oncol (2013) 1.31
Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov (2013) 1.27
Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov (2013) 1.22
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism. J Clin Invest (2014) 1.22
A Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. N Engl J Med (2015) 1.22
The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med (2013) 1.18
Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement. Chest (2015) 1.11
Analysis of MicroRNAs in sputum to improve computed tomography for lung cancer diagnosis. J Thorac Oncol (2014) 1.11
Invited commentary: epidemiologic studies of the impact of air pollution on lung cancer. Am J Epidemiol (2013) 1.07
Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med (2014) 1.04
Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst (2014) 1.04
Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene (2012) 1.03
A propensity-matched analysis of wedge resection and stereotactic body radiotherapy for early stage lung cancer. Ann Thorac Surg (2014) 1.01
Noninvasive urinary metabolomic profiling identifies diagnostic and prognostic markers in lung cancer. Cancer Res (2014) 1.00
MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 1.00
An official American Thoracic Society/European Respiratory Society statement: the role of the pulmonologist in the diagnosis and management of lung cancer. Am J Respir Crit Care Med (2013) 0.99
Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor. Cancer Res (2011) 0.97
Interactions between cigarette smoking and fine particulate matter in the Risk of Lung Cancer Mortality in Cancer Prevention Study II. Am J Epidemiol (2014) 0.96
Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis. Cancer Prev Res (Phila) (2014) 0.96
Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics (2014) 0.95
Asbestos exposure, pleural plaques, and the risk of death from lung cancer. Am J Respir Crit Care Med (2014) 0.93
Characterizing the molecular spatial and temporal field of injury in early-stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) (2012) 0.92
Airway basal cells of healthy smokers express an embryonic stem cell signature relevant to lung cancer. Stem Cells (2013) 0.90
Reconstructing targetable pathways in lung cancer by integrating diverse omics data. Nat Commun (2013) 0.90
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol (2014) 0.89
Biomarkers to help guide management of patients with pulmonary nodules. Am J Respir Crit Care Med (2013) 0.89
Diagnosis and subtyping of de novo and relapsed mediastinal lymphomas by endobronchial ultrasound needle aspiration. Am J Respir Crit Care Med (2013) 0.85
Balancing curability and unnecessary surgery in the context of computed tomography screening for lung cancer. J Thorac Cardiovasc Surg (2013) 0.85
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications. Am J Respir Crit Care Med (2014) 0.84
Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer. Am J Respir Crit Care Med (2014) 0.84
Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila) (2013) 0.83
Biomarkers to the rescue in a lung nodule epidemic. J Clin Oncol (2014) 0.82
HOIL-1L functions as the PKCζ ubiquitin ligase to promote lung tumor growth. Am J Respir Crit Care Med (2014) 0.81
Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer. Am J Respir Crit Care Med (2014) 0.80
Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis. Am J Respir Crit Care Med (2014) 0.80
Balancing the benefits and harms of low-dose computed tomography screening for lung cancer: Medicare's options for coverage. Ann Intern Med (2014) 0.78
Implementing lung cancer screening under Medicare: the last chance to get it right? JAMA (2014) 0.76
The Asthma Mobile Health Study, a large-scale clinical observational study using ResearchKit. Nat Biotechnol (2017) 0.89
Integrated Genomics Reveals Convergent Transcriptomic Networks Underlying Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 0.85
Update in Lung Cancer 2015. Am J Respir Crit Care Med (2016) 0.75